Revance Therapeutics (NASDAQ:RVNC) Now Covered by StockNews.com

StockNews.com started coverage on shares of Revance Therapeutics (NASDAQ:RVNC - Free Report) in a report issued on Saturday. The brokerage issued a hold rating on the biopharmaceutical company's stock.

A number of other equities research analysts also recently weighed in on the stock. William Blair restated a "market perform" rating on shares of Revance Therapeutics in a research note on Monday, August 12th. Guggenheim reiterated a "neutral" rating on shares of Revance Therapeutics in a report on Monday, August 12th. HC Wainwright downgraded Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 13th. Needham & Company LLC restated a "hold" rating on shares of Revance Therapeutics in a research report on Monday, October 28th. Finally, Piper Sandler downgraded Revance Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 12th. Nine analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. According to MarketBeat, Revance Therapeutics presently has a consensus rating of "Hold" and an average price target of $10.29.

Revance Therapeutics Price Performance

Shares of RVNC opened at $5.80 on Friday. The firm has a 50 day simple moving average of $5.78 and a two-hundred day simple moving average of $4.36. Revance Therapeutics has a one year low of $2.30 and a one year high of $9.74. The company has a market cap of $607.96 million, a P/E ratio of -1.82 and a beta of 0.98.

Revance Therapeutics (NASDAQ:RVNC - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.48) by $0.12. The business had revenue of $65.39 million for the quarter, compared to analyst estimates of $66.30 million. Revance Therapeutics's quarterly revenue was up 20.2% on a year-over-year basis. During the same period last year, the firm posted ($0.80) EPS. On average, analysts expect that Revance Therapeutics will post -1.53 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

A number of hedge funds have recently made changes to their positions in RVNC. Capital World Investors raised its holdings in Revance Therapeutics by 16.8% during the 1st quarter. Capital World Investors now owns 13,945,535 shares of the biopharmaceutical company's stock worth $68,612,000 after purchasing an additional 2,006,459 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Revance Therapeutics by 342.1% in the first quarter. BNP Paribas Financial Markets now owns 211,695 shares of the biopharmaceutical company's stock valued at $1,042,000 after buying an additional 163,809 shares during the period. Integral Health Asset Management LLC bought a new stake in Revance Therapeutics during the second quarter valued at $1,285,000. Vanguard Group Inc. grew its holdings in Revance Therapeutics by 6.5% during the 1st quarter. Vanguard Group Inc. now owns 5,398,406 shares of the biopharmaceutical company's stock worth $26,560,000 after acquiring an additional 328,781 shares during the period. Finally, Blair William & Co. IL lifted its stake in shares of Revance Therapeutics by 3.6% in the 1st quarter. Blair William & Co. IL now owns 329,267 shares of the biopharmaceutical company's stock valued at $1,620,000 after purchasing an additional 11,318 shares during the period. 97.70% of the stock is currently owned by institutional investors.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.